The objective of the current study was to develop and optimize a sublingual tablet of Losartan potassium, which is an effective drug in the treatment of hypertension. Owing to number of advantages dissociated with the quick onset of action and it by passes the liver. Sublingual tablets offer effective and easier way for management of Hypertension. The basic approach used in development of Sublingual tablet was the use of super disintegrates by direct compression method. Oral mucosal drug delivery is one of the promising method of systemic drug delivery which offers several advantages. The literal meaning sublingual is ''under the tongue''. Hence the method includes the administrating drug via mouth so that it is absorbed via blood vessels (systemic) present under the tongue. Sublingual tablet is tablet that dissolves or disintegrates in the oral cavity without need of drinking water. Sublingual tablet traditionally have been used as an effective method to improve the dissolution properties and bioavailability of water-soluble drugs. In the preformulation studies, Losartan potassium was characterized by its physiochemical properties such as melting point, solubility, partition coefficient, UV and FTIR studies. UV spectroscopic method was established for quantitative estimation of the drug and the absorbtion maxima were 234 nm. The tablets were formulated by using the direct compression technique. The post compression studies i.e. shape, size, weight variation, hardness, friability and wetting time determined the quality of the product.
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[55] www.ajprd.com/AJPRD mucosa may be potential site for controlled or sustained drug delivery. Oral route is most preferred route by medical practitioners and manufacturer due to highest acceptability of patients. About 60% of all dosage forms available are the oral solid dosage form. The lower bioavailability, long onset time and dysphagia patients turned the manufacturer to the parenterals and liquid orals. But the liquid orals (syrup, suspension, emulsion etc) have the problem of accurate dosing mainly and parenterals are painful drug delivery, so most patient incompliance.
The target sites for local drug delivery in the oral cavity include the following: Buccal, Sublingual, Periodontal region, Tongue, Gum. Other desirable targeting sites adjacent to oral cavity include pharynx, larynx, adenoids and tonsils. Sublingual administration can offer an attractive alternative route of administration. The advantage of the sublingual drug delivery is that the drug can be directly absorbed into systemic circulation bypassing enzyme degradation in the gut and liver. In addition, the thin sublingual mucosa (about 190 μm compared to 500-800 μm of the buccal mucosa) and the abundance of blood supply at the sublingual region allow excellent drug penetration (absorption) to achieve high plasma drug concentration with a rapid onset of action. A well-established example is nitroglycerin, which is used for the treatment of acute angina 1 .
Overview of the oral mucosa:-
The anatomical and physiological properties of the oral mucosa have been extensively reviewed by several authors. The oral cavity comprises the lips, cheek, tongue, hard palate, soft palate and floor of the mouth. The lining of the oral cavity is referred to as the oral mucosa, and includes the buccal, sublingual, gingival, palatal and labial mucosa. The buccal, sublingual and the mucosal tissues at the ventral surface of the tongue account for about 60% of the oral mucosal surface area.
The top quarter to one-third of the oral mucosa is made up of closely compacted epithelial cells. The primary function of the oral epithelium is to protect the underlying tissue against potential harmful agents in the oral environment and from fluid loss. Beneath the epithelium are the basement membrane, lamina propia and submucosa. The oral mucosa also contains many sensory receptors including the taste receptors of the tongue. Three types of oral mucosa can be found in the oral cavity; the lining mucosa is found in the outer oral vestibule (the buccal mucosa) and the sublingual region (floor of the mouth). The specialized mucosa is found on the dorsal surface of tongue, while the masticatory mucosa is found on the hard palate (the upper surface of the mouth) and the gingiva (gums). The lining mucosa comprises approximately 60%, the masticatory mucosa approximately 25%, and the specialized mucosa approximately 15% of the total surface area of the oral mucosal lining in an adult human. The masticatory mucosa is located in the regions particularly susceptible to the stress and strains resulting from masticatory activity 2 .
Sublingual delivery: Systemic drug delivery through the sublingual route had emerged from the desire to provide immediate onset of pharmacological effect.
Dysphagia (difficulty in swallowing) is a common problem of all age groups, especially elderly, children, and patients who are mentally retarted, uncooperative, nauseated or on reduced liquid intake/diets have difficulties in swallowing these dosage forms. Sublingual administration of the drug means placement of the drug under the tongue and drug reaches directly in to the blood stream through the ventral surface of the tongue and floor of the mouth 3 . cancer patients. This newly developed galenic formulation with a higher early systemic exposure and a shorter T max compared with oral trans mucosalfentanyl citrate makes a particularly suitable formulation for the management of BTP in opioid-treated cancer patients due to the rapid onset of action [5] [6] .
Fig.1:-Overview of Oral Mucosa

PRE-FORMULATION STUDIES:-
Physical Appearance
Physical appearance of drug was examined by its various organoleptic properties like color, state, odor and taste.
Melting Point Determination
The melting point of a solid is defined as the temperature at which the solid and liquid are in equilibrium at a total pressure of 1 atm. experimentally, melting point is actually as a range of temperature in which the first crystal starts to melt until the temperature at which the last crystal just disappears.
Solubility
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Qualitative Solubility of Losartan potassium in Different Solvents
The solubility was carried out in different solvents like methanol, phosphate buffer, and acetone. A pinch of Losartan potassium was added into separate test tubes, containing 5 ml of each solvent. The entire test tubes were shaken for 5-10 min. Then the solubility was visually determined.
Quantitative Solubility of Losartan potassium in Different Solvents
Pure Losartan potassium was added to 10 ml of phosphate buffer pH 6.8 in 25 ml volumetric flasks. The volumetric flasks was capped properly and shaken at temp. 37±2 °C in a temperature controlled water bath (Shaking water bath) for 48 hr. Resultant samples containing undissolved solid dispersions suspended in the volumetric flasks was filtered through Whatman filter paper, suitably diluted with phosphate buffer pH 6.8 and analyzed by UV spectrophotometer at 234 nm. 
Determination of Absorption Maxima (λ max )
A UV absorption maxima of the drug was determined by scanning (10 μg/ml) solution with phosphate buffer between 200-400 nm.
Partition Coefficient
Partition coefficient is a measurement of drug's lipophilicity and its ability to cross cell membrane. The partition coefficient of Losartan potassium was determined in n-octanol: phosphate buffer. 50 mg of drug was accurately weighed and added to 50 ml of noctanol: phosphate buffer, in a separating funnel. The mixture was shaken until equilibrium was attained. Phases were separated in separating funnel and phosphate buffer was filtered through Whatman filter no. 41 and was accordingly The amount of Losartan potassium solublized in phosphate buffer was determined by measuring the absorbance at 234 nm using UV spectrophotometer. The partition coefficient was calculated and compared with literature value 6 .
P o/w = C organic / C aqueous
Preparation of Standard Curve
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Preparation of Phosphate Buffer 6.8
Dissolved 27.218g of Potassium dihydrogen phosphate in water and diluted with water upto 1000ml to make 0.2M Potassium Dihydrogen Phosphate.
Dissolved 8g of Potassium NaOH in water and made volume upto 1000ml to make 0.2M NaOH.
250 ml of 0.2 M potassium dihydrogen phosphate and 112 ml of 0.2N sodium hydroxide was placed in 1000 ml volumetric flask and then added distilled water to volume make up the mark.
Preparation of Calibration Curve in Phosphate Buffer pH 6.8
100 mg of Losartan Potassium was weighed accurately and dissolved in pH 6.8 phosphate buffer in a 100 ml volumetric flask and volume was made up to the mark with pH 6.8 phosphate buffer. The concentration of this standard stock solution was 1000µg/ml. From this stock solution, aliquots of 0.2ml, 0.4ml, 0.6ml, 0.8ml,1ml and 1.2ml were transferred to 10 ml volumetric flasks and volume was made up to 10 ml with phosphate buffer pH 6.8 and solution of varying concentration are 2, 4, 6, 0, 10 and 12µg/ml were obtained respectively. The absorbance of these solutions was measured at 234 nm against a blank phosphate buffer pH 6.8.
PREPARATION OF PRELIMINARY TRIAL BATCHES
13-14
Preliminary trial batches containing selected inclusion complexes were prepared by direct compression method using single punch tablet machine to produce convex faced tablets weighed 80 mg using a set of die punch 8 mm.
ISSN: 2320-4850
[57] www.ajprd.com/AJPRD Where; m = weight of powder or granules (gm), Vb = Bulk Volume (cm 3 ), π = 22/7 = 3.14, r = Radius of Cylinder (cm), h = Height reached by powder in cylinder (cm).
Tapped density (ρt) = m/vt =m/π2rh
Where; m = weight of powder or granules (gm), v = Tapped Volume (cm 3 ), π = 22/7 = 3.14, r = Radius of Cylinder (cm), h = Height reached by powder in cylinder after tapping (cm).
Carr's Index = (ρt -ρb/ρt) × 100
Where; ρt = tapped density, ρb= bulk density. Hausner's Ratio (Hr) = Tapped density/ bulk density Lower Hausner's ratio (<1.25) indicates better flow properties than higher ones (>1.25).
Angle of Repose (θ)
calculated using the following equation. 
17-20
After doing the in-vitro dissolution study, the in-vitro dissolution data is fit into various experimental: 
Korsemeyer-Peppas Model:
This model describes the drug release from a polymeric system. To find out the mechanism of drug release, first 60% drug release data were fitted in Korsemeyer-Peppas model.
Mt/M ͚ = Ktn
Where; Mt/M ͚ = fraction of drug release at time t, K = release rate constant, n = release exponent that characterizes different release mechanisms for different release mechanism for different geometrical shaped matrices.
Result:-PREFORMULATION STUDIES:-Physical Appearance and Melting Point
The Sample of Losartan potassium was analysed for various organoleptic, physicochemical and spectrophotometric methods. The sample possesses similar colour, odour, taste and texture as given in officials (Indian pharmacopoeia). The FTIR Spectrum of Losartan potassium is shown in Fig 5. 1. FTIR spectra verified the purity and authenticity of the procured sample. 
PREPARATION OF CALIBRATION CURVES
The calibration curves of Losartan potassium were found to be linear in the concentration range of 0-20 μg/ml in phosphate buffer (pH 6.8).
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In-vitro release studies were carried out using tablet dissolution test apparatus paddle method at 37±0.5°C, taking 500 ml of pH 6.8 phosphate buffer as dissolution medium. Speed of rotation of the paddle was set at 50 rpm. Aliquots of 5 ml were withdrawn after 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 min and analyzed spectrophotometrically at 234 nm.
Formulation F6 prepared by direct compression showed release 98.46% drug at the end of 10 min. The in-vitro dissolution profile ( Fig.5.7 ) indicated faster and maximum drug release from formulation F6. The rapid drug dissolution might be due to easy breakdown of particles due to CCS and rapid absorption of drugs into the dissolution medium. Slope values signify that the release rate follows first order kinetics.
Comparison with marketed preparation showed better results of F6 in in-vitro dissolution profile.
STABILITY STUDY
The stability method can be defined as validated quantitative analytical method that can detect the change with time in the chemical, physical or microbiological properties of the drug substance and drug product, and that are so specific that the content of active ingredients, degradation can be accurately measured without interference.
Test design
The product was properly filled in aluminum foil and was stored according to storage conditions. 
Testing Plan
Formulation F6 was put in aluminum foil and was stored at the following storage conditions. Data are expressed as mean ± SD (n=3) 
